[1]张焰,饶莉.心脏淀粉样变性诊疗进展[J].心血管病学进展,2015,(5):527-530.[doi:10.3969/j.issn.1004-3934.2015.05.001]
　ZHANG Yan,RAO Li.Advances in Diagnosis and Treatment of Cardiac Amyloidosis[J].Advances in Cardiovascular Diseases,2015,(5):527-530.[doi:10.3969/j.issn.1004-3934.2015.05.001]
点击复制

心脏淀粉样变性诊疗进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2015年5期
页码:
527-530
栏目:
主题综述
出版日期:
2016-05-20

文章信息/Info

Title:
Advances in Diagnosis and Treatment of Cardiac Amyloidosis
作者:
张焰; 饶莉
四川大学华西医院心内科,四川 成都 610041
Author(s):
ZHANG Yan;  RAO Li
Department of Cardiology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China
关键词:
心脏淀粉样变性;  分型;  早期诊断
Keywords:
cardiac amyloidosis;  classification;  early diagnosis
分类号:
R542.2
DOI:
10.3969/j.issn.1004-3934.2015.05.001
文献标志码:
A
摘要:
心脏淀粉样变性是淀粉样物质在心脏沉积所致的心肌疾病,诊治难度大,预后不佳。其主要表现与治疗方案与临床分型有关。早期诊断和治疗该疾病有助于改善预后。
Abstract:
Cardiac amyloidosis is a cardiomyopathy caused by the deposition of amyloidogenic protein in the heart.The clinical manifestations and therapy methods associate with clinical classification. Early diagnosis and treatment can improve the prognosis of disease.

参考文献/References:

[1] Sharma N,Howlett J.Current state of cardiac amyloidosis[J].Curr Opin Cardiol,2013,28(2):242-248.
[2] Sher T, Gertz MA. Recent advances in the diagnosis and management of cardiac amyloidosis[J]. Future Cardiol,2014,10(1):131-146.
[3] Pinney JH,Smith CJ,Taube JB,et al.Systemic amyloidosis in England: an epidemiological study[J]. Br J Haematol,2013,161(4):525-532.
[4] Sikkink LA,Ramirez-Alvarado M. Cytotoxicity of amyloidogenic immunoglobulin light chains in cell culture[J]. Cell Death Dis,2010,1:e98.
[5] Kyle RA,Linos A,Beard CM,et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County,Minnesota,1950 through 1989[J]. Blood,1992,79(7):1817-1822.
[6] Patel KS,Hawkins PN. Cardiac amyloidosis:where are we today?[J].J Intern Med,2015,278(2):126-144.
[7] Westermark P, Sletten K,Johansson B,et al. Fibril in senile systemic amyloidosis is derived from normal transthyretin[J]. Proc Natl Acad Sci USA,1990,87(7):2843-2845.
[8] Ng B,Connors LH,Davidoff R,et al.Senile systemic amyloidosis presenting with heart failure:a comparison with light chain-associated amyloidosis[J].Arch Intern Med,2005, 165(12):1425-1429.
[9] Merlini G,Bellotti V.Molecular mechanisms of amyloidosis[J].N Engl J Med, 2003,349(6):583-596.
[10] Plante-Bordeneuve V. Update in the diagnosis and management of transthyretin familial amyloid polyneuropathy[J]. J Neurol,2014,261(6):1227-1233.
[11] Cadinanos J, Costa R, Trujillo D,et al.Systemic secondary AA amyloidosis[J].Med Clin(Barc),2015,144(7):324-330.
[12] Millucci L,Ghezzi L,Bernardini G,et al.Prevalence of isolated atrial amyloidosis in young patients affected by congestive heart failure[J]. Sci World J,2012,2012:293863.
[13] Dispenzieri A,Gertz MA,Kyle RA,et al.Serum cardiac troponins and N-terminal pro-brain natriuretic peptide:a staging system for primary systemic amyloidosis[J]. J Clin Oncol,2004,22(18):3751-3757.
[14] Kumar S,Dispenzieri A,Lacy MQ,et al.Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements[J]. J Clin Oncol,2012,30(9):989-995.
[15] Ishiguro K,Hayashi T,Igarashi T,et al.Decrease of B-type natriuretic peptide to less than 200 pg/mL predicts longer survival in cardiac immunoglobulin light chain amyloidosis[J]. Int J Hematol,2015,102(2):200-204.
[16] Dispenzieri AS. Soluble ST2(sST2)is a novel valuable prognostic marker among patients with immunoglobulin light chain(AL)Amyloidosis [abstract OP-33] [R].Presented at the XIVth international symposium on amyloidosis,2014.
[17] Cyrille NB,Goldsmith J,Alvarez J,et al. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis[J]. Am J Cardiol, 2014,114(7):1089-1093.
[18] Sayed RH,Rogers D,Khan F,et al.A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis[J]. Eur Heart J,2015,36(18):1098-1105.
[19] Feng D,Edwards WD,Oh JK,et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis[J]. Circulation,2007,116(21):2420-2426.
[20] Buss SJ,Emami M,Mereles D,et al. Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis:incremental value compared with clinical and biochemical markers[J]. J Am Coll Cardiol,2012,60(12):1067-1076.
[21] Phelan D,Collier P,Thavendiranathan P,et al.Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis[J]. Heart,2012,98(19):1442-1448.
[22] Quarta CC,Solomon SD,Uraizee I,et al.Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis[J]. Circulation,2014,129(18):1840-1849.
[23] Dungu JN,Valencia O,Pinney JH,et al.CMR-based differentiation of AL and ATTR cardiac amyloidosis[J]. JACC Cardiovasc Imaging,2014,7(2):133-142.
[24] White JA, Kim HW, Shah D,et al.CMR imaging with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis[J]. JACC Cardiovasc Imaging,2014,7(2):143-156.
[25] Hutt DF,Quigley AM,Page J,et al. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis[J]. Eur Heart J Cardiovasc Imaging,2014,15(11):1289-1298.
[26] Bokhari S,Castano A,Pozniakoff T,et al.(99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses[J].Circ Cardiovasc Imaging,2013,6(2):195-201.
[27] Antoni G,Lubberink M,Estrada S,et al.In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET[J]. J Nucl Med,2013,54(2):213-220.
[28] Dorbala S,Vangala D,Semer J,et al.Imaging cardiac amyloidosis: a pilot study using 18F-florbetapir positron emission tomography[J]. Eur J Nucl Med Mol Imaging, 2014,41(9):1652-1662.
[29] Granstam SO,Rosengren S,Vedin O,et al.Evaluation of patients with cardiac amyloidosis using echocardiography, ECG and right heart catheterization[J]. Amyloid, 2013,20(1):27-33.
[30] Shah KB,Inoue Y,Mehra MR.Amyloidosis and the heart:a comprehensive review[J]. Arch Intern Med,2006,166(17):1805-1813.
[31] Rubinow A,Skinner M,Cohen AS.Digoxin sensitivity in amyloid cardiomyopathy[J]. Circulation,1981,63(6):1285-1288.
[32] Kristen AV,Dengler TJ,Hegenbart U,et al. Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death[J]. Heart Rhythm,2008,5(2):235-240.
[33] Gertz MA,Lacy MQ,Dispenzieri A,et al. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis:importance of achieving a complete response[J]. Haematologica,2007,92(10):1415-1418.

相似文献/References:

[1]杜明亮 郑晓群.心脏淀粉样变性临床研究进展[J].心血管病学进展,2022,(7):636.[doi:【DOI】10.16806/j.cnki.issn.1004-3934.2022.07.000]
[2]孙晓昕 方纬 张宇辉.99mTc-焦膦酸盐单光子显像：心脏淀粉样变性分型诊断的新应用[J].心血管病学进展,2023,(1):21.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.006]
　SUN Xiaoxin,FANG Wei,ZHANG Yuhui.99mTc-Pyrophosphate Scintigraphy:New application in Diagnosis and Classification of Cardiac Amyloidosis[J].Advances in Cardiovascular Diseases,2023,(5):21.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.006]
[3]侯为洁 龚艳君.心脏磁共振在心脏淀粉样变性中的应用进展[J].心血管病学进展,2023,(9):796.[doi:10.16806/j.cnki.issn.1004-3934.2023.09.007]
　HOU Weijie,GONG Yanjun.Application of Cardiac Magnetic Resonance in Cardiac Amyloidosis[J].Advances in Cardiovascular Diseases,2023,(5):796.[doi:10.16806/j.cnki.issn.1004-3934.2023.09.007]

备注/Memo

备注/Memo:
作者简介:张焰(1990—),在读硕士,主要从事扩张型心肌病应用基础研究。Email: 857497061@qq.com 通信作者:饶莉,教授,博士生导师,博士,主要从事扩张型心肌病基础与临床研究及心脏功能超声评价研究。Email: lrlz1989@163.com
更新日期/Last Update: 2016-05-20